Frank Rimerman Advisors LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,086 shares of the biopharmaceutical company’s stock after purchasing an additional 2,252 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Gilead Sciences were worth $2,690,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Manning & Napier Advisors LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $25,328,000. Legal & General Group Plc grew its stake in Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after buying an additional 93,068 shares in the last quarter. GSA Capital Partners LLP bought a new position in Gilead Sciences in the 1st quarter valued at about $462,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after buying an additional 33,162 shares in the last quarter. Finally, Cetera Investment Advisers boosted its position in shares of Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after acquiring an additional 119,909 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.
Insider Activity
In related news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,033,340 in the last quarter. 0.16% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
View Our Latest Analysis on GILD
Gilead Sciences Trading Up 0.2 %
GILD opened at $89.00 on Friday. The stock has a market cap of $110.80 billion, a PE ratio of 108.54, a price-to-earnings-growth ratio of 3.07 and a beta of 0.18. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $89.74. The company has a fifty day moving average of $82.46 and a 200-day moving average of $73.44.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 3.76 EPS for the current year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 375.61%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- How to Buy Cheap Stocks Step by Step
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Use the MarketBeat Excel Dividend Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Canadian Penny Stocks: Can They Make You Rich?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.